Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Two papers published in Science provide the first clinical evidence that fecal microbial transplants (FMTs) can boost the anti-cancer efficacy of immune checkpoint inhibitors. At least eight microbiome companies have launched first-in-human trials pairing their microbiome agents with approved immunotherapies (Table 1) to satisfy the growing need to increase the proportion of patients responding to checkpoint inhibitors.